The PennZone

  • Home
  • Business
  • Health
  • Construction
  • Entertainment
  • Technology
  • Travel
  • Legal
  • Music

Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
The PennZone/10323446

Trending...
  • Claude Riveloux Review 2026: How the $10B Fund Manager Dispels 'Scam' Rumors Through Education
  • Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
  • Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
SafeBreak Generation 2 Patent Lineus Medical
FAYETTEVILLE, Ark. - PennZone -- Lineus Medical, the leader in vascular access innovation, has been awarded a U.S. patent for SafeBreak® Vascular Generation 2, the next evolution of the company's flagship breakaway device. The newly patented design features a single-valve system, replacing the original device's two-valve configuration. The ideas captured in the patent allow the device to have a significantly smaller profile while maintaining the device's core function of protecting IV lines from damaging external forces by separating. The patent also includes the ability to add a light and/or sound notification for nurses when the device separates. The current version of SafeBreak relies on IV pump alarm to alert nurses of a separation. Having an alarm on SafeBreak will help open up the home healthcare and gravity line IV market for the company.

SafeBreak Vascular is the only breakaway device for IV lines clinically proven to reduce multiple IV complications.¹ When a damaging force is placed on the line, SafeBreak intentionally separates to remove the force and protect the patient's IV.   When separation occurs, valves on both ends of the device close to prevent medication leakage from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money.1

More on The PennZone
  • The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
  • Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
  • RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
  • Award-Winning Director Crystal J. Huang's Under-$50K Film "The Ritual House" Wins Best Horror Feature at Golden State Film Festival
  • Grads aren't getting hired — here's what we're doing about it

"Lineus Medical continues to innovate and be the thought leader both clinically and scientifically in the breakaway device market.", said Vance Clement, CEO of Lineus Medical. "SafeBreak Gen 2 will move us closer to accomplishing our mission of removing the pains associated with IV lines for patients, nurses, and hospitals."

"The SafeBreak Gen 2 design reflects our ongoing commitment to the continuous improvement of SafeBreak," said Will Armstrong, COO of Lineus Medical. "This patent showcases how our engineering team is advancing breakaway device technology with smarter, simpler design solutions that improve patient care while further strengthening the company's intellectual property portfolio."

About Lineus Medical

Lineus Medical is the developer of SafeBreak® Vascular, a breakaway technology proven to reduce IV restarts and IV complications.¹ More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.

References:

1. Data on file.

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
  • The Franchise King® Releases Free Guide for Nervous Buyers
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
  • Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples
  • Matthew Sisneros Releases Raw and Unfiltered Memoir: The Devil Lost Another One — A Powerful Story of Crime, Consequence, and Redemption
  • From Life to Light: Jess L. Martinez Shares a Soulful Poetry Collection That Explores What It Means to Be Human
  • Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
  • South Philadelphia Filmmakers Launch Fourth Feature Film on Amazon Prime Video
  • Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
  • 46th International Symposium On Forecasting – Dates, Venue And Speakers Announced
  • Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
  • Bonavita Luxury & Portable Lavatories Announces Rebrand to Bonavita Site Solutions
  • Multi Location SEO Guide: Rank in Multiple Cities and Generate Consistent Leads

Popular on PennZone

  • OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors - 136
  • Still Using Ice? FrostSkin Reinvents Hydration - 109
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
  • Deep Learning Robotics (DLRob) Announces Pre-Launch of Zero-Teach and Teach-by-Demonstration Technology for Kitting Applications
  • The Legal AI Showdown: Westlaw, Lexis, ChatGPT… or EvenSteven?
  • TL International Group Becomes First Global Operator to Fully Migrate to Pulsant's Dedicated Car Rental Cloud
  • Excel Signworks Introduces Custom Lobby Signs to Help Pittsburgh Businesses Elevate First Impressions in 2026
  • Grand Opening: New Single-Family Homes Now Open for Sale at Heritage at Manalapan
  • The World's No.1 Superstar® Brings Disco Fever Back With New Global Single and Video "Disco Dancing"

Similar on PennZone

  • $6 Million Funding Secured as Retail Expansion, Operational Streamlining, and Asset-Light Strategy Position the Company for Accelerated Growth $SOWG
  • L-Tron Returns from a Successful PACK EXPO East Conference
  • K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
  • Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us